| Document |
Document Title |
|
JP2023538753A |
Disclosed herein are detectable moieties and detectable conjugates comprising one or more detectable moieties. In some embodiments, the disclosed detectable moieties have narrow wavelengths and are suitable for multiplexing. Also disclos...
|
|
JP2023538325A |
Described herein are chlorpromazine, methods of making such compounds, and the use of such compounds to treat cancer, inflammatory diseases or conditions, or diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease...
|
|
JP7335002B2 |
Provided is an enantiomer preparation method in which one enantiomer of a sulfoxide compound is selectively prepared, the sulfoxide compound having a sulfur atom of a sulfoxide group as an asymmetric center, and the method comprising: a ...
|
|
JP7308764B2 |
A process for continuous dissolution of a solid in a reaction medium includes: (a) providing a liquid by withdrawal of a portion of the reaction medium from a first reaction vessel; (b) contacting the liquid provided in (a) with the soli...
|
|
JP7308816B2 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therape...
|
|
JP2023527961A |
Novel compounds have been disclosed that act as antagonists to the human GPR39 protein. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using antagonists in t...
|
|
JP2023524415A |
[Chemical 1] The present invention relates to modified lysines of formula (I). The invention further relates to polypeptides comprising one or more modified lysine residues, pharmaceutical delivery systems comprising these polypeptides, ...
|
|
JP2023515614A |
The present disclosure provides methods for making 3,7-bis-(dimethylamino)-phenothiazin-5-ium chlorides of formula (I). The method comprises preparing a wet crude of 3,7-dibromophenothiazin-5-ium bromide (III) from phenothiazine (II) wit...
|
|
JP7253646B2 |
To provide a novel π-conjugated compound capable of improving luminous efficiency of an organic electroluminescent element, for example.The π-conjugated compound is represented by general formula (1) (where Q1 to Q3 each independently ...
|
|
JP2023513241A |
The present invention relates to compounds of formula (I). The compounds can be used to antagonize the interferon gene stimulating factor (STING) protein, thereby causing liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis...
|
|
JP2023512786A |
Provided are compounds of formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of formu...
|
|
JP2023036081A |
To provide a new phenothiazine compound, a synthesis method of the phenothiazine compound, and a resin composition containing the phenothiazine compound, and the resin composition which is applicable to a coating material, ink, an adhesi...
|
|
JP7237017B2 |
It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy m...
|
|
JP2023506572A |
The present invention relates to compounds suitable for use in electronic devices and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
JP2023011886A |
To provide a method for preparing 3,7-bis(dimethylamino)phenothiazin-5-ylium iodide, the method being very simple to implement and providing high purity and high yield.The method uses phenothiazine as a starting material and comprises th...
|
|
JP7203018B2 |
Provided herein are compounds useful as inhibitors of CBX. Also described are pharmaceutical compositions and medical uses of these compounds.
|
|
JP7200261B2 |
The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.
|
|
JP2022185177A |
To provide a novel phenothiazine derivative compound that can be easily copolymerized with polymerizable unsaturated monomer, and a manufacturing method thereof.The invention provides a phenothiazine derivative compound represented by th...
|
|
JP2022174272A |
To provide methods for treating diseases.Provided herein are compounds useful as inhibitors of CBX. Also described are pharmaceutical compositions and medical uses of these compounds. The invention also relates to methods of treating or ...
|
|
JP7165062B2 |
To provide a phenothiazine derivative represented by the general formula [I] (R1: a C4-20 monovalent hydrocarbon group, with carbon at α-position with respect to a carbonyl group being tertiary carbon, and R-Ar: an aralkyl group, its R ...
|
|
JP7159161B2 |
The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I) wherein variables A, R1, R2, R2', R3, R4, and R5 of Formula (I) are def...
|
|
JP7149971B2 |
The present invention relates to: a process for preparing 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide or chloride; a method of converting 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide to 3,7-bis-(dimethylamino)-phenothiazin-5...
|
|
JP7149271B2 |
The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2', R3, R4, R5, R6, and R7 of Formula I are def...
|
|
JP2022141896A |
To provide phenothiazine derivative compounds and salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications.The present disclosure provides phenothiazine derivative compound...
|
|
JP7125941B2 |
The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused...
|
|
JP7113055B2 |
The present disclosure provides phenothiazine derivative compounds and salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of disease...
|
|
JP7105012B2 |
Red-emitting platinum (II) Schiff base complexes with high emission quantum efficiency are prepared. These materials can be used to fabricate OLEDs.
|
|
JP2022090304A |
To provide a phenothiazine derivative compound that can be easily copolymerized with a polymerizable unsaturated monomer, and a production method thereof.The phenothiazine derivative compound is represented by general formula [I], where ...
|
|
JP7081898B2 |
To provide a novel π-conjugated compound capable of improving luminous efficiency of an organic electroluminescent element, for example.The π-conjugated compound is represented by general formula (1) (where Qto Qeach independently repr...
|
|
JP2022068343A |
To provide a method for producing 3,7-bis(dimethylamino)phenothiazine-5-ylium iodide, the method resulting in high purity and high yield while being very simple to implement.The production method uses phenothiazine as a starting material...
|
|
JP7027711B2 |
A positive resist composition comprising a polymer adapted to be decomposed under the action of acid to increase its solubility in alkaline developer and a sulfonium compound of specific structure has a high resolution. When the resist c...
|
|
JP2022509091A |
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and their use in the treatment of hemoglobin-mediated disorders.
|
|
JP7002617B2 |
To provide an oxime ester derivative compound having superior sensitivity, heat resistance, chemical resistance, and curing properties; and to provide a photopolymerization initiator and photosensitive composition containing the same.Thi...
|
|
JP2022506898A |
In one embodiment, a compound of formula AA, or a pharmaceutically acceptable salt thereof, characterized by or pharmaceutically acceptable salt thereof. The variables shown in Formula A are as defined in the claims. [Chemical 1]
|
|
JP2022502436A |
The present invention relates to compounds that can be used as active compounds in organic electronic devices, in particular compounds for use in electronic devices. The present invention further relates to a method for producing a compo...
|
|
JPWO2020145250A1 |
To provide a compound having a 15-PGDH inhibitory action. A compound represented by the general formula (1) or a pharmacologically acceptable salt thereof. [Selection diagram] None
|
|
JP2021152646A |
To provide a resist material having high sensitivity, low LWR and low CDU regardless of whether it is used as a positive resist material or a negative resist material, and a pattern forming process using the same.A resist material compri...
|
|
JP6926133B2 |
The present application relates to a compound of a formula (I) which comprises a benzene group that is substituted with a group selected from carbazole derivatives and bridged amines and with an electron attracting group, wherein the two...
|
|
JP6902031B2 |
Provided are the following: a sulfonium salt which does not contain a toxic metal and which exhibits higher cationic polymerization performance and crosslinking performance than a tetrakis(pentafluorophenyl)borate salt; a heat- or photo-...
|
|
JP6861644B2 |
Thermally Activated Delayed Fluorescence (TADF) compounds wherein two aromatic heterocyclic moieties are provided as acceptor groups, spaced apart from two donor moieties by an aromatic spacer ring, are described. Charged organic TADF sp...
|
|
JP6856725B2 |
The present invention relates to novel dendrimer conjugates, methods for their preparation and their use for treatment of diseases. The invention discloses a new method for the delivery of dendrimer conjugates with therapeutically active...
|
|
JP6849615B2 |
The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the ...
|
|
JP6845931B2 |
The present invention relates to a photoinitiator and a light-shielding photosensitive resin composition containing the same and, more specifically, to: a photoinitiator comprising compounds of two or more groups selected from a group of...
|
|
JP6836791B2 |
Provided is a method for producing a perfluoroalkylated compound at low cost, safely and with high efficiency. A method for producing a perfluoroalkylated compound, comprising reacting a bis(perfluoroalkanoyl) peroxide with a compound ha...
|
|
JP6807337B2 |
The present disclosure provides phenothiazine derivative compounds and salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of disease...
|
|
JP2020203910A |
To provide a monosubstituted or polysubstituted amphiphilic hypocrellin derivative, and use of the derivative for production of a photosensitizer drug for photodynamic therapy.The amphiphilic hypocrellin derivative is represented by the ...
|
|
JP6790256B2 |
The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such comp...
|
|
JP6769414B2 |
A resist composition comprising a 2,5,8,9-teraaza-1-phosphabicyclo[3.3.3]undocane, biguanide or phosphazene salt of an iodinated aromatic group-containing carboxylic acid exhibits a sensitizing effect and an acid diffusion suppressing ef...
|
|
JP2020147604A |
To design and synthesize a new NSAIA prodrug that is positively charged and can be administered transdermally.A positively-charged NSAIA prodrug is designed and synthesized which has a chemical structure 1, 2a, 2b, 2c, or 2d. A positivel...
|
|
JP2020125284A |
To provide fluoropolymers and methods for forming and using the fluoropolymers.The invention provides compounds represented by formula (I). (Ris H, substituted/unsubstituted C-Calkyl, or the like; Qand Qare O, or S; Qand Qare H, amino, o...
|
